Wall Street Zen Downgrades MaxCyte (NASDAQ:MXCT) to Sell

MaxCyte (NASDAQ:MXCT) was downgraded by Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued on Monday.

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of MaxCyte in a report on Monday, December 29th. One investment analyst has rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, MaxCyte has an average rating of “Hold” and a consensus price target of $6.00.

MaxCyte Trading Down 2.2%

Shares of NASDAQ MXCT opened at $0.74 on Monday. The company has a market capitalization of $78.94 million, a P/E ratio of -1.68 and a beta of 1.22. MaxCyte has a 12 month low of $0.64 and a 12 month high of $3.12. The stock has a 50 day moving average of $0.88 and a 200-day moving average of $1.33.

MaxCyte (NASDAQ:MXCT) last posted its quarterly earnings results on Tuesday, March 24th. The company reported ($0.09) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.01). MaxCyte had a negative net margin of 132.57% and a negative return on equity of 23.50%. The business had revenue of $6.76 million during the quarter, compared to the consensus estimate of $9.16 million. Analysts predict that MaxCyte will post -0.42 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Prudential Financial Inc. bought a new position in shares of MaxCyte during the second quarter worth approximately $26,000. State of Wyoming bought a new stake in shares of MaxCyte in the second quarter valued at approximately $38,000. Dynamic Technology Lab Private Ltd acquired a new stake in MaxCyte during the second quarter worth approximately $40,000. Kwmg LLC grew its position in MaxCyte by 75.8% during the third quarter. Kwmg LLC now owns 25,833 shares of the company’s stock worth $41,000 after buying an additional 11,135 shares in the last quarter. Finally, Jain Global LLC bought a new position in MaxCyte during the 4th quarter worth $45,000. Institutional investors and hedge funds own 68.81% of the company’s stock.

Key Headlines Impacting MaxCyte

Here are the key news stories impacting MaxCyte this week:

• Positive Sentiment: Strong cash position and runway — MaxCyte reported $155.6M in cash, cash equivalents and investments as of 12/31/25 and said it expects to finish 2026 with at least ~$136M, which supports operations and program investment despite near-term revenue pressure. GlobeNewswire Results & Guidance
• Positive Sentiment: EPS in some reports beat expectations — Zacks noted a Q4 loss of $0.06 vs its consensus loss of $0.08, which can be interpreted as a modest beat on EPS metrics depending on the data source. Zacks Q4 Note
• Neutral Sentiment: 2026 revenue guidance set at $30–32M (Core $25–27M; SPL-related ~$5M) — guidance implies a slight step-down from FY2025 revenue of $33M, so investors should weigh growth trajectory versus cash runway and contract timing. Guidance Detail
• Neutral Sentiment: New CFO appointment — Parmeet Ahuja will become CFO on March 30, 2026, replacing the previously announced transition; management continuity is generally neutral-to-positive but will be monitored. CFO Appointment
• Neutral Sentiment: Short-interest reporting appears erroneous/zero — multiple feeds show “0 shares” and NaN increases for March short interest; data inconsistency means short-interest is not a clear market driver from these entries. (No link — consolidated data entries)
• Negative Sentiment: Revenue and some earnings metrics missed some analyst expectations — MarketBeat and other feeds reported Q4 revenue around $6.75–7.3M with revenue below some consensus estimates, and one report showed EPS missing consensus, contributing to downward pressure. MarketBeat Earnings
• Negative Sentiment: Analyst downgrade — Wall Street Zen downgraded MXCT to Sell on March 23, adding near-term bearish sentiment from the sell-side. Downgrade Article

MaxCyte Company Profile

MaxCyte, Inc (NASDAQ: MXCT) is a clinical‐stage cell therapy platform company that develops and commercializes proprietary flow electroporation technology for the delivery of macromolecules into living cells. The company’s instruments and consumables are designed to support research, preclinical development and clinical‐scale manufacturing of cell therapies across a variety of modalities, including engineered T cells, natural killer (NK) cells and induced pluripotent stem cell (iPSC) therapies.